Comparable stake leader
Israel Biotech Fund I, L.P.
SEC ownership of Ayala Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001100397.
Disclosed value leader
Israel Biotech Fund I, L.P.
Comparable rows
0/7
Latest evidence
01 Mar 2024
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Israel Biotech Fund I, L.P.
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
01 Mar 2024
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001100397
- Issuer location
- Monmouth Junction, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Ayala Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Israel Biotech Fund I, L.P.
Disclosed value leader
Israel Biotech Fund I, L.P.
Comparable rows
0/7
Latest evidence
01 Mar 2024
3/4/5
Highest disclosed value: $10,052,361
7 rows are not safely comparable across share classes.
Quick read
Israel Biotech Fund I, L.P. has the largest disclosed position value at $10.05M.
0 of 7 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Israel Biotech Fund I, L.P.'s linked filing trail.
Disclosed position value
Top 4
Israel Biotech Fund I, L.P.
$10.05M
aMoon Growth Fund Limited Partner...
$224.2K
Yuval Cabilly
$271K
David Sidransky
$55
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-7 of 7 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Israel Biotech Fund I, L.P. |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$10,052,361
59,518,403 shares
mixed-class rows
|
— | 01 Mar 2024 |
| aMoon Growth Fund Limited Partnership |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$224,241
560,602 shares
|
— | 18 Oct 2023 |
| Yuval Cabilly |
3/4/5
Director
|
—
class O/S missing
|
$270,954
677,386 shares
|
— | 18 Oct 2023 |
| David Sidransky |
3/4/5
Director
|
—
mixed-class rows
|
$55
2,481 shares
mixed-class rows
|
— | 19 Jan 2023 |
| Murray A. Goldberg |
3/4/5
Director
|
—
class O/S missing
|
—
1,171 shares
|
— | 19 Jan 2023 |
| Robert J. Spiegel |
3/4/5
Director
|
—
class O/S missing
|
—
1,171 shares
|
— | 19 Jan 2023 |
| Vered Bisker-Leib |
3/4/5
Director
|
—
class O/S missing
|
—
1,171 shares
|
— | 19 Jan 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 15 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to Ayala Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Israel Biotech Fund I, L.P.
Net 12M change
$0
Latest report
01 Mar 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Israel Biotech Fund I, L.P. | Director, 10%+ Owner | $10,052,361 | Mixed | 01 Mar 2024 | ||
| Yuval Cabilly | Director | $270,954 | Mixed | 18 Oct 2023 | ||
| aMoon Growth Fund Limited Partnership | 10%+ Owner | $224,241 | Mixed | 18 Oct 2023 | ||
| David Sidransky | Director | $55 | Mixed | 19 Jan 2023 | ||
| Murray A. Goldberg | Director | Mixed | 19 Jan 2023 | |||
| Robert J. Spiegel | Director | Mixed | 19 Jan 2023 | |||
| Roy Golan | Chief Financial Officer | Mixed | 18 Oct 2023 | |||
| Pini Orbach | Director | Mixed | 18 Oct 2023 | |||
| Bridget A. Martell | Director | Mixed | 18 Oct 2023 | |||
| Vered Bisker-Leib | Director | Mixed | 19 Jan 2023 |
Recent insider transactions for Ayala Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.